Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)
US11136386B2 · kind B2 · utility
2Cited by
31References
53Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 10, 2020 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | Dec 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.